Charles River Laboratories (CRL) Tops Q3 EPS by 17c, provides guidance
Tweet
Share
E-mailGet Alerts CRL Hot Sheet
Price: $288.50 -1.65%
Revenue Growth %: -4.3%
Financial Fact:
Net sales related to services: 292.85M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -4.3%
Financial Fact:
Net sales related to services: 292.85M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Charles River Laboratories (NYSE: CRL) reported Q3 EPS of $2.59, $0.17 better than the analyst estimate of $2.42. Revenue for the quarter came in at $1.01 billion versus the consensus estimate of $976 million.
GUIDANCE:
Charles River Laboratories sees FY2024 EPS of $10.10-$10.30, versus the consensus of $10.00.
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- Goldman Sachs Downgrades Shurgard Self Storage SA (SHUR:BB) to Neutral
- JPMorgan Upgrades Whitehaven Coal Ltd. (WHC:AU) (WHITF) to Overweight
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
